Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validation of TYK2 and exploration of PRSS36 as drug targets for psoriasis using Mendelian randomization.

Scientific reports - 13 Oct 2024

Guo Xin, Tao Meng-Jun, Ji XinCan, Han MengQi, Shen Yue, Hong Cheng, Guo HaoYang, Shi Wei, Yuan Hui

Abstract excerpt

Psoriasis is a chronic inflammatory skin disorder with multiple causes, including genetic and environmental factors. Despite advances in treatment, there remains a need to identify novel therapeutic targets. A Mendelian randomization (MR) analysis was conducted to identify therapeutic targets for psoriasis. Data on cis-expression quantitative trait loci were obtained from the eQTLGen Consortium (n = 31,684)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Predisposition to Disease
Share to Genome-Wide Association Study

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mendelian Randomization Analysis

Share to Molecular Docking Simulation

Share to Polymorphism, Single Nucleotide

Share to Psoriasis

Share to Quantitative Trait Loci

Share to TYK2 Kinase

Source

Open in PubMed Open full text

Identifiers

PMID: 39397091
DOI: 10.1038/s41598-024-74148-3
PMCID: PMC11471773

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validation of TYK2 and exploration of PRSS36 as drug targets for psoriasis using Mendelian randomization.PMID 39397091Read ↗

Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases.Semantic proximity Read ↗

Characterising a Novel Therapeutic Target for Psoriasis, TYK2, Using Functional Genomics.Semantic proximity Read ↗

Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for PsoriasisSemantic proximity Read ↗

Proteome-wide Mendelian randomization and colocalization analysis identify potential drug targets for psoriasisSemantic proximity Read ↗

Integrated multi-omics strategies for identifying novel therapies in psoriasis.Semantic proximity Read ↗

Systematic druggable genome-wide Mendelian randomization identifies novel therapeutic targets or repurposing opportunities for rheumatoid arthritisSemantic proximity Read ↗

Exploring novel drug targets for atopic dermatitis through plasma proteome with genome.Semantic proximity Read ↗

Genetic association of lipid and lipid-lowering drug target genes with atopic dermatitis: a drug target Mendelian randomization study.Semantic proximity Read ↗

Exploring genetic targets of psoriasis using genome wide association studies (GWAS) for drug repurposingSemantic proximity Read ↗

Phenome-wide Mendelian randomization analysis reveals new risk factors for 4 inflammatory skin diseases.Semantic proximity Read ↗

Exploring Genetic Drug Targets in Acne Vulgaris: A Comprehensive Proteome‐Wide Mendelian Randomization StudySemantic proximity Read ↗

Identification of potential drug targets for rheumatoid arthritis from genetic insights: a Mendelian randomization studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.